Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.

Verified November 2008 by Center for Supporting Hematology-Oncology Trials.
Recruitment status was: Recruiting

Sponsor:

Collaborator:

Bayer

Information provided by:

Center for Supporting Hematology-Oncology Trials

ClinicalTrials.gov Identifier:

NCT00137787

First received: August 28, 2005

Last updated: November 11, 2008

Last verified: November 2008

History of Changes

Purpose

The aim of this study is to investigate whether intravenous ciprofloxacin is as effective as cefepime for the initial treatment of febrile neutropenia developed in patients with hematologic diseases.

Condition	Intervention	Phase
Febrile Neutropenia	Drug: ciprofloxacin Drug: cefepime	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Randomized Controlled Trial Comparing Ciprofloxacin With Cefepime in Febrile Neutropenic Patients With Hematologic Diseases

Resource links provided by NLM:

Genetics Home Reference related topics: cyclic neutropenia

MedlinePlus related topics: Blood Disorders Fever

Drug Information available for: Ciprofloxacin Ciprofloxacin hydrochloride Cefepime Cefepime hydrochloride

Genetic and Rare Diseases Information Center resources: Granulocytopenia

U.S. FDA Resources

Further study details as provided by Center for Supporting Hematology-Oncology Trials:

Primary Outcome Measures:

Treatment efficacy [ Time Frame: At 7 days after initiating therapy ]

Secondary Outcome Measures:

Treatment efficacy [ Time Frame: At 21 days ]
Toxicity [ Time Frame: During the follow-up period ]


Estimated Enrollment:	200
Study Start Date:	April 2005
Estimated Study Completion Date:	March 2010
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1	Drug: ciprofloxacin
Active Comparator: 2	Drug: cefepime

Detailed Description:

Infectious complications during neutropenic periods are major causes of morbidity and mortality especially for patients with hematological diseases, and prompt initiation of antibiotic therapy is warranted for those who develop febrile neutropenia. As for initial therapeutic agents, beta-lactam antibiotics, i.e., third- or fourth-generation cephalosporins and carbapenems have been used frequently because of their strong and broad-spectrum of action. However, under these conditions, development of resistance mediated by a beta-lactamase is concerned, and there is a need for alternative non-beta-lactam antibiotics for this indication. Ciprofloxacin is a potent agent covering against wide range of strains including Pseudomonas aeruginosa, and expected as a potential candidate. We have therefore planned a prospective randomized controlled trial designed to compare intravenous ciprofloxacin with cefepime for febrile neutropenic patients.

Eligibility


Ages Eligible for Study:	15 Years to 79 Years (Child, Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Hematologic disease
Ages between 15 and 79 years
Axillary temperature of 38.0 C or greater on one occasion or of 37.5 to 37.9 C lasting for more than 1 hour
Absolute neutrophil count of less than 500/microL
T-Bil level less than 2.0 times the upper limit of normal
Cre level less than 1.5 times the upper limit of normal
Written informed consent

Exclusion Criteria:

Past history of allergic reaction to the study drug
Positive for HIV antibody
Pregnant or lactating women
Family history of auditory disturbance
Having received systemic antibacterial therapy within 14 days
Receiving systemic antifungal or antiviral therapy except fluconazole or acyclovir for cases undergoing transplantation
No recovery of neutrophil count of 1,000/microL or higher from the previous febrile episode
On treatment with ketoprofen
On treatment with sodium valproate
Septic shock

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00137787

Contacts


Contact: Yoshiko Atsuta, MD	81-52-719-1973	y-atsuta@med.nagoya-u.ac.jp
Contact: Ritsuro Suzuki, MD		r-suzuki@med.nagoya-u.ac.jp

Locations


Japan
Nagoya University Graduate School of Medicine	Recruiting
Nagoya, Japan, 466-8550
Contact: Yoshiko Atsuta, MD 81-52-719-1973 y-atsuta@med.nagoya-u.ac.jp
Principal Investigator: Tomoki Naoe, MD

Sponsors and Collaborators

Center for Supporting Hematology-Oncology Trials

Bayer

Investigators


Study Director:	Yoshiko Atsuta, MD	Nagoya University

More Information


ClinicalTrials.gov Identifier:	NCT00137787 History of Changes
Other Study ID Numbers:	C-SHOT 0402
Study First Received:	August 28, 2005
Last Updated:	November 11, 2008

Keywords provided by Center for Supporting Hematology-Oncology Trials:


febrile neutropenia hematologic disease

Additional relevant MeSH terms:


Neutropenia Fever Hematologic Diseases Febrile Neutropenia Agranulocytosis Leukopenia Leukocyte Disorders Body Temperature Changes Signs and Symptoms Cefepime Cephalosporins	Ciprofloxacin Anti-Bacterial Agents Anti-Infective Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Cytochrome P-450 CYP1A2 Inhibitors Cytochrome P-450 Enzyme Inhibitors

ClinicalTrials.gov processed this record on May 25, 2017

To Top